|
Pathogen (Target Population)
|
Vaccine Envisaged
|
Annualized Present Value of Potential Health Benefits (IME Units)
|
Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits (dollars)
|
|
Dengue virus
(Infants and children in endemic areas; travelers to endemic areas)
|
Attenuated live vector virus containing gene for broadly cross-reacting protective antigen
|
9,558
|
241,803,765
|
|
Escherichia coli
(enterotoxigenic)
(Infants < 6 months)
|
A combination of purified colonization factor antigens and possibly other antigens
|
126,454
|
722,284,852
|
|
Genetically engineered attenuated strains
|
145,260
|
69,171,586
|
|
Hemophilus influenzae type b
(Infants)
|
Conjugated polysaccharide
|
210,943
|
526,603,421
|
|
Hepatitis A virus
(Susceptibles of all ages; children)
|
Attenuated live virus
|
15,112
|
1,058,021,429
|
|
Polypeptide recombinant vaccine produced in yeast
|
14,392
|
4,028,950,683
|
|
Hepatitis B virus
(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations)
|
Polypeptide produced by recombinant DNA technology
|
213,192
|
8,859,258,746
|
|
Japanese encephalitis virus
(Children in epidemic and and endemic areas; foreign visitors to epidemic regions)
|
Inactivated virus produced in cell culture
|
3,232
|
613,959,820
|
|
Mycobacterium leprae
(Immuno-prophylactic: all children in endemic areas. Immuno-therapeutic: all recently infected individuals)
|
Armadillo-derived M. leprae
|
88,481
|
270,619,575
|
|
Neisseria meningitidis
(Infants, 3–6 months)
|
Conjugated capsular polysaccharides, groups A,C,Y, and W135
|
13,754
|
708,114,155
|
|
Parainfluenza viruses
(Infants)
|
Trivalent, subunit vaccine (which must contain fusion proteins)
|
43,692
|
1,697,123,972
|
|
Plasmodium spp.
(All infants at risk, military personnel, travelers)
|
Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation
|
475,205
|
967,271,590
|
|
Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)
|
426,640
|
856,843,460
|
